Cycloalkyl derivatives as inhibitors of bone resorption and...

Details Cycloalkyl derivatives as inhibitors of bone resorption and... Cycloalkyl derivatives as inhibitors of bone resorption and...

2002-05-10

2008-03-25

Coleman, Brenda (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S275000, C514S303000, C514S359000, C514S381000, C514S383000, C514S395000, C514S398000, C544S284000, C544S292000, C544S331000, C544S332000, C546S118000, C548S251000, C548S255000, C548S265400, C548S308100, C548S332100

Reexamination Certificate

active

07348333

ABSTRACT:
There are described cycloalkyl derivatives of the formula (I)in-line-formulae description="In-line Formulae" end="lead"?R1—Y-A-B-D-E-F-G  (I)in-line-formulae description="In-line Formulae" end="tail"?in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

REFERENCES:
patent: 5397796 (1995-03-01), Zoller et al.
patent: 5981492 (1999-11-01), Zoller et al.
patent: 6017925 (2000-01-01), Duggan
patent: 6340679 (2002-01-01), Peyman et al.
patent: 6399620 (2002-06-01), Wehner et al.
patent: 6602878 (2003-08-01), Carniato et al.
patent: B-34988/93 (1993-05-01), None
patent: 0 518 586 (1992-12-01), None
patent: 0 528 586 (1993-02-01), None
patent: 0 528 587 (1993-02-01), None
patent: 0 566 919 (1993-10-01), None
patent: 97112198.3 (2000-03-01), None
patent: WO 93/18057 (1993-09-01), None
patent: WO 94/08577 (1994-04-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/14008 (1995-05-01), None
patent: WO 95/32710 (1995-12-01), None
patent: WO 96/00574 (1996-01-01), None
patent: WO 96/00730 (1996-01-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 98/31359 (1998-07-01), None
Miller et al., Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic, Journal of Medicinal of Chemistry, vol. 43, No. 1, pp. 22-26, 2000.
Friedlander et al. “Definition of Two Angiogenic Pathways by Distance avIntegins,”Science(Dec. 1995), vol. 270, pp. 1500-1502.
Brown et al. “Stimulation of migration of human aortic smooth muscel cells by vitronection: implications for atherosclerosis”,Cardiovascular Research(1994), vol. 28, pp. 1815-1820.
Fisher et al. “Inhibition of osteoclastic bone resorption in vivo by echistatin, and ‘arginyl-gycyl-aspartyl’ (RDG)-containing protein,”Endocrinology, vol. 132, No. 3, pp. 1411-1413, 1993.
Sato et al. “Echistatis is a potent inhibitor of bone resorption in culture,”J. Cell Bio. (Oct. 1990), vol. 111, pp. 1713-1723.
Horton et al. “Arg-Gly-Asp (RDG) peptides and Anti-Vitronectin Receptor Antibody,”Experimental Cell Research, (1991), vol. 195, pp. 368-375.
Brooks et al. “Integrin avβ3antagonists promote tumor regression by inducing apoptosis,”Cell(Dec. 1994), vol. 79, pp. 1157-1164.

Affiliated with

Also associated with

Rating

Cycloalkyl derivatives as inhibitors of bone resorption and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cycloalkyl derivatives as inhibitors of bone resorption and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl derivatives as inhibitors of bone resorption and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3966020